Grand Pharmaceutical Overview
- Year Founded
-
1995
- Status
-
Public
- Employees
-
12,326
- Stock Symbol
-
00512
- Investments
-
45
- Share Price
-
$0.55
- (As of Friday Closing)
Grand Pharmaceutical General Information
Description
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
Contact Information
Website
www.grandpharm.comCorporate Office
- 23rd Floor, City Plaza
- Number 160 Qiaokou Road, Qiaokou District
- Wuhan, Hubei 430034
- China
Corporate Office
- 23rd Floor, City Plaza
- Number 160 Qiaokou Road, Qiaokou District
- Wuhan, Hubei 430034
- China
Grand Pharmaceutical Stock Performance
As of 13-Nov-2026, Grand Pharmaceutical’s stock price is $0.55. Its current market cap is $1.93B with 3.5B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.55 | $0.55 | $0.53 - $1.14 | $1.93B | 3.5B | 4.37M | $0.04 |
Grand Pharmaceutical Financials Summary
As of 30-Jun-2026, Grand Pharmaceutical has a trailing 12-month revenue of $1.6B.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,458,521 | 3,923,882 | 2,456,096 | 2,135,483 |
| Revenue | 1,597,890 | 1,575,526 | 1,492,311 | 1,344,911 |
| EBITDA | 194,290 | 286,154 | 452,381 | 374,726 |
| Net Income | 141,989 | 159,162 | 316,326 | 240,126 |
| Total Assets | 3,585,070 | 3,491,226 | 3,219,059 | 2,881,298 |
| Total Debt | 644,200 | 606,880 | 572,235 | 435,642 |
Grand Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Grand Pharmaceutical Comparisons
Industry
Financing
Details
Grand Pharmaceutical Competitors (21)
One of Grand Pharmaceutical’s 21 competitors is Novartis, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novartis | Corporation | Basel, Switzerland | ||||
| Torrent Pharmaceuticals | Corporation | Ahmedabad, India | ||||
| Cipla | Corporation | Mumbai, India | ||||
| Aurobindo Pharma | Corporation | Hyderabad, India | ||||
| Sun Pharmaceutical Industries | Corporation | Mumbai, India |
Grand Pharmaceutical Signals
Grand Pharmaceutical Investments & Acquisitions (45)
Grand Pharmaceutical’s most recent deal was a Later Stage VC with Cavendish (Drug Discovery). The deal was made on 22-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cavendish (Drug Discovery) | 22-Oct-2026 | Later Stage VC | Drug Discovery | ||
| Tianjin Tanabe | 22-Jul-2024 | Merger/Acquisition | Pharmaceuticals | ||
| Xeltis | 30-Jun-2023 | Later Stage VC | Therapeutic Devices | ||
| BlackSwan Vascular | 24-Apr-2023 | Merger/Acquisition | Medical Supplies | ||
| Hubei Bafeng Pharmaceutical | 07-Aug-2022 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology |
Grand Pharmaceutical ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
28.45 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Grand Pharmaceutical Exits (5)
Grand Pharmaceutical’s most recent exit was on 01-Jan-2022 from Cloudbreak Pharma. The exit was categorized as with 11 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Cloudbreak Pharma | 01-Jan-2022 | Completed |
|
||
| Cloudbreak Pharma | 16-Apr-2020 | Completed |
|
||
| Oncosec Medical | 10-Feb-2020 | Completed |
|
||
| Conavi Medical | 15-Nov-2017 | Completed |
|
||
| Henan Lihua Pharmaceutical | 30-Apr-2010 | Merger/Acquisition | Completed |
Grand Pharmaceutical Affiliates
Subsidiaries (9)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Shenzhen Sun God Sales | Shenzhen, China | 2004 | |
| Puer Weiye | Beijing, China | 2004 | |
| Hubei Bafeng Pharmaceutical | Enshi, China | 1997 | |
| Zhejiang Xianle | Taizhou, China | 1995 | |
| Tianjin Tanabe | Tianjin, China | 1993 |
Grand Pharmaceutical FAQs
-
When was Grand Pharmaceutical founded?
Grand Pharmaceutical was founded in 1995.
-
Where is Grand Pharmaceutical headquartered?
Grand Pharmaceutical is headquartered in Wuhan, China.
-
What is the size of Grand Pharmaceutical?
Grand Pharmaceutical has 12,326 total employees.
-
What industry is Grand Pharmaceutical in?
Grand Pharmaceutical’s primary industry is Drug Discovery.
-
Is Grand Pharmaceutical a private or public company?
Grand Pharmaceutical is a Public company.
-
What is Grand Pharmaceutical’s stock symbol?
The ticker symbol for Grand Pharmaceutical is 00512.
-
What is the current stock price of Grand Pharmaceutical?
As of 13-Nov-2026 the stock price of Grand Pharmaceutical is $0.55.
-
What is the current market cap of Grand Pharmaceutical?
The current market capitalization of Grand Pharmaceutical is $1.93B.
-
What is Grand Pharmaceutical’s current revenue?
The trailing twelve month revenue for Grand Pharmaceutical is $1.6B.
-
Who are Grand Pharmaceutical’s competitors?
Novartis, Torrent Pharmaceuticals, Cipla, Aurobindo Pharma, and Sun Pharmaceutical Industries are some of the 21 competitors of Grand Pharmaceutical.
-
What is Grand Pharmaceutical’s annual earnings per share (EPS)?
Grand Pharmaceutical’s EPS for 12 months was $0.04.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process